TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active

TOVX stock is trading higher in pre-market action after Theriva Biologics announced a licensing deal for SYN-020. The shares are up about +12% and volume is running well above average. Investors are tracking the cash and milestone terms, and traders list TOVX among the most active names this session. We review the deal specifics, trading data, and what the move means for shareholders on AMEX in the United States.

TOVX stock pre-market trade and volume

TOVX stock opened the pre-market session with a notable move from the prior close of $0.19 to a pre-market quote near $0.21. Reported intraday range shows a day low $0.20 and day high $0.26. Volume has exploded to 274,439,837 shares versus an average volume of 5,252,256, giving a relative-volume spike of about 51.35x. The surge places TOVX among today’s most active U.S. AMEX listings and explains the sharp price reaction.

Deal details behind the TOVX stock move

Theriva licensed SYN-020 to Rasayana Therapeutics and received $300,000 upfront plus up to $38,000,000 in milestone payments and tiered royalties. Rasayana will fund further development and commercialization, shifting near-term clinical costs off Theriva’s balance sheet. The licensing news is the primary driver of the pre-market rally and is confirmed in corporate releases and market outlets GlobeNewswire source. The Nasdaq recap also summarized the terms and market response Nasdaq source.

Fundamentals and valuation for TOVX stock

Theriva Biologics (TOVX) shows a small market cap of roughly $7.57M on AMEX in the United States. Price averages are 50-day $0.20 and 200-day $0.39, indicating short-term strength versus a weaker longer-term trend. Key accounting metrics include cash per share $0.78, book value per share $0.70, and a reported current ratio 0.90, which signal limited liquidity headroom. Investors should note the company reports a market-cap weighted balance and clinical-stage operating profile rather than recurring revenue.

Technicals and trading signals for TOVX stock

Technically, TOVX shows neutral momentum with RSI 47.15 and ADX 13.26, indicating no strong trend yet. Short-term indicators show Bollinger bands at 0.17–0.21 and ATR near $0.02, so the current move is volatile on a low-price base. On-chain trading data reveals an OBV reading consistent with the heavy volume spike. Traders should use tight risk controls given the stock’s high relative volume and small float dynamics.

Catalysts, pipeline and risks for TOVX stock

Theriva retains lead oncology assets such as VCN-01 while out-licensing SYN-020 to focus capital on cancer programs. The next formal earnings or corporate update is scheduled for 2026-04-01, which could reset expectations. Key risks include clinical trial outcomes, limited liquidity, and a low current ratio. Positive catalysts include milestone payments from Rasayana and any clinical progress on VCN-01 that would re-rate the stock.

Meyka AI grade and forecast for TOVX stock

Meyka AI rates TOVX with a score out of 100: 62.81 (Grade B) — Suggestion: HOLD. This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, analyst signals, and forecasts. Meyka AI’s forecast model projects a near-term quarterly target of $0.48 versus the current price USD 0.1967, implying an upside of 144.06%. Forecasts are model-based projections and not guarantees. For more detail, see the Meyka stock page for TOVX: Meyka TOVX page.

Final Thoughts

TOVX stock is a small-cap, high-volatility play driven today by the SYN-020 licensing announcement. The deal delivers a $300,000 upfront payment and potential milestone and royalty income up to $38,000,000, which reduces Theriva’s near-term funding needs. Trading shows extreme volume, with 274,439,837 shares changing hands versus a 5,252,256 average. Meyka AI assigns a 62.81/100 B grade (HOLD) based on sector and financial comparisons. Our practical price targets for investors: conservative $0.10, base $0.20, and bullish $0.48 (Meyka quarterly model). Longer-term, success in the VCN-01 oncology program could justify higher valuation, while failed trials or capital shortfalls would pressure shares. Remember, forecasts are model projections and not guarantees. Use risk limits and stay alert to milestone and clinical updates for TOVX on AMEX in the United States.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.